Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1985 Mar;19(3):329–333. doi: 10.1111/j.1365-2125.1985.tb02651.x

Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.

R V Lewis, M S Lennard, P R Jackson, G T Tucker, L E Ramsay, H F Woods
PMCID: PMC1463731  PMID: 2859048

Abstract

The pharmacokinetics and pharmacodynamics of atenolol and timolol were studied in six extensive and four poor metabolisers of debrisoquine. There was a significant correlation between the debrisoquine to 4-hydroxydebrisoquine ratio and the area under the plasma concentration time curve (AUC) for timolol (rs = 0.75, P less than 0.02). The mean of the AUC values for timolol was significantly greater in the poor metabolisers than in the extensive metabolisers (P less than 0.05). There was a significant correlation between the debrisoquine to 4-hydroxydebrisoquine ratio and beta-adrenoceptor blockade 24 h after dosing with timolol (rs = 0.66, P less than 0.05). The mean degree of beta-adrenoceptor blockade was significantly greater in the poor metabolisers than in the extensive metabolisers 24 h after dosing with timolol (P less than 0.01). There was no relation between the debrisoquine to 4-hydroxydebrisoquine ratio and the pharmacokinetics or pharmacodynamics of atenolol.

Full text

PDF
329

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvan G., von Bahr C., Seidemann P., Sjöqvist F. High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet. 1982 Feb 6;1(8267):333–333. doi: 10.1016/s0140-6736(82)91583-5. [DOI] [PubMed] [Google Scholar]
  2. Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 Apr;17(2):102–105. doi: 10.1136/jmg.17.2.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ferguson R. K., Vlasses P. H., Koplin J. R., Holmes G. I., Huber P., Demetriades J., Abrams W. B. Relationships among timolol doses, plasma concentrations and beta-adrenoceptor blocking activity. Br J Clin Pharmacol. 1982 Nov;14(5):719–725. doi: 10.1111/j.1365-2125.1982.tb04963.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Freestone S., Silas J. H., Lennard M. S., Ramsay L. E. Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing. Br J Clin Pharmacol. 1982 Nov;14(5):713–718. doi: 10.1111/j.1365-2125.1982.tb04962.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kitchen I., Tremblay J., André J., Dring L. G., Idle J. R., Smith R. L., Williams R. T. Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica. 1979 Jul;9(7):397–404. doi: 10.3109/00498257909038744. [DOI] [PubMed] [Google Scholar]
  6. Lennard M. S., Silas J. H., Freestone S., Ramsay L. E., Tucker G. T., Woods H. F. Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med. 1982 Dec 16;307(25):1558–1560. doi: 10.1056/NEJM198212163072505. [DOI] [PubMed] [Google Scholar]
  7. Sloan T. P., Mahgoub A., Lancaster R., Idle J. R., Smith R. L. Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J. 1978 Sep 2;2(6138):655–657. doi: 10.1136/bmj.2.6138.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Tocco D. J., Duncan A. E., Delauna F. A., Hucker H. B., Gruber V. F., Vandenheuvel W. J. Physiological disposition and metabolism of timolol in man and laboratory animals. Drug Metab Dispos. 1975 Sep-Oct;3(5):361–370. [PubMed] [Google Scholar]
  9. Wang T., Roden D. M., Wolfenden H. T., Woosley R. L., Wood A. J., Wilkinson G. R. Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther. 1984 Mar;228(3):605–611. [PubMed] [Google Scholar]
  10. Wasson B. K., Scheigetz J., Rooney C. S., Hall R. A., Share N. N., VandenHeuvel W. J., Arison B. H., Hensens O. D., Ellsworth R. L., Tocco D. J. Urinary metabolites of timolol from humans and laboratory animals. Syntheses and beta-adrenergic blocking activities. J Med Chem. 1980 Nov;23(11):1178–1184. doi: 10.1021/jm00185a006. [DOI] [PubMed] [Google Scholar]
  11. Yee Y. G., Rubin P., Blaschke T. F. Atenolol determination by high-performance liquid chromatography and fluorescence detection. J Chromatogr. 1979 Apr 1;171:357–362. doi: 10.1016/s0021-9673(01)95315-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES